Kisqali and Osteopenia - a phase IV clinical study of FDA data

Summary:

Osteopenia is reported as a side effect among people who take Kisqali (ribociclib succinate), especially for people who are female, 50-59 old, have been taking the drug for 2 - 5 years also take Letrozole, and have Breast cancer.

The phase IV clinical study analyzes which people have Osteopenia when taking Kisqali. It is created by eHealthMe based on reports of 25,037 people who have side effects when taking Kisqali from the FDA, and is updated regularly.

What is Kisqali?

Kisqali has active ingredients of ribociclib succinate. eHealthMe is studying from 25,050 Kisqali users. Check the latest studies of Kisqali.

What is Osteopenia?

Osteopenia (a condition where bone mineral density is lower than normal) is found to be associated with 1,435 drugs and 1,172 conditions by eHealthMe. Check the latest studies of Osteopenia.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 30, 2026

25,037 people reported to have side effects when taking Kisqali.
Among them, 34 people (0.14%) have Osteopenia.

Among these 34 people:

How long have people been on Kisqali when they have Osteopenia? *

What is the gender of people who have Osteopenia when taking Kisqali? *

female: 100 %
male: 0.0 %

What is the age of people who have Osteopenia when taking Kisqali? *

What are other drugs people take besides Kisqali? *

Letrozole: 23 people, 67.65%
Pregabalin: 11 people, 32.35%
Hydromorphone Hydrochloride: 11 people, 32.35%
Xgeva: 4 people, 11.76%
Faslodex: 4 people, 11.76%
Fulvestrant: 3 people, 8.82%
Xeloda: 2 people, 5.88%
Exemestane: 2 people, 5.88%
Zometa: 1 person, 2.94%
Femara: 1 person, 2.94%

What are other side effects people have besides Osteopenia? *

Fatigue (feeling of tiredness): 29 people, 85.29%
Nausea (feeling of having an urge to vomit): 26 people, 76.47%
Diarrhea: 24 people, 70.59%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 16 people, 47.06%
Nausea And Vomiting: 16 people, 47.06%
Hair Loss: 15 people, 44.12%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 13 people, 38.24%
Dizziness: 12 people, 35.29%
Diverticulitis (digestive disease which involves the formation of pouches (diverticula) within the bowel wall): 11 people, 32.35%
Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect): 11 people, 32.35%

What are the existing conditions these people have? *

Breast Cancer: 18 people, 52.94%
Breast Cancer Metastatic: 14 people, 41.18%
Pain: 11 people, 32.35%
Fibromyalgia (a long-term condition which causes pain all over the body): 11 people, 32.35%
High Blood Pressure: 7 people, 20.59%
Bone Disorder: 4 people, 11.76%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 1 person, 2.94%

* Approximation only. Some reports may have incomplete information.

Do you take Kisqali and have Osteopenia?

- Check whether Osteopenia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Kisqali:

Kisqali (25,050 reports)

Osteopenia treatments and more:

Osteopenia (46,948 reports)

Browse all side effects of Kisqali:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Osteopenia:

Osteopenia (1,435 drugs)

Browse all the conditions that are associated with Osteopenia:

Osteopenia (1,172 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ribociclib succinate (the active ingredients of Kisqali) and Kisqali (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.